#United States #Miami #Pacira BioSciences #DOMA Capital #Director Candidates

DOMA Perpetual Capital Management Announces Director Nominations for Pacira BioSciences

In a strategic move that underscores its investment in Pacira BioSciences, DOMA Perpetual Capital Management LLC has declared its intention to nominate four independent director candidates for the 2025 annual meeting of stockholders. Holding approximately 4.14% of Pacira's outstanding common stock, DOMA is poised to make significant waves within the biopharmaceutical company by advocating for a shift in corporate governance.

Commitment to Pacira's Potential

DOMA's management has expressed a robust conviction regarding the value encapsulated in Pacira’s intellectual property. Given the biotech's innovations and market potential, DOMA perceives the current share valuation as significantly understated. In this light, DOMA is pressing for immediate action from Pacira's board of directors. They are advocating for a stock tender offer, proposing the buyback of 10 million shares using the cash on hand to optimize shareholder value.

This push aligns with Pacira's already endorsed $150 million buyback strategy, which aims to leverage the company’s healthy cash flow. DOMA's approach is a reflection of their broader investment philosophy, which seeks companies demonstrating sustainable competitive advantages within attractive sectors.

Expertise and Strategy

DOMA Perpetual Capital Management is situated in the heart of Miami, Florida, and employs a fundamentals-driven strategy aimed at discovering and investing in firms globally, across various sectors and market caps. Their methodology emphasizes minimizing downside risk while maximizing potential returns, making this nomination effort consistent with their overall investment principles.

In their recent communication, DOMA enlisted the legal expertise of Olshan Frome Wolosky LLP to navigate their engagement with Pacira, ensuring that their proposed changes receive the most professional and structured advocacy during the upcoming stockholder meeting.

Importance of Stockholder Engagement

The nomination of these independent candidates is not just about company governance but reflects a broader trend of increased stockholder activism in corporate America. Investors are becoming more vocal about directing corporate strategies that align with enhancing shareholder returns. DOMA’s actions could prompt other investors to consider similar initiatives within their investee companies, indicating a potential shift towards shareholder-centric governance in the sector.

As the date of the annual meeting approaches, DOMA urges existing shareholders to familiarize themselves with the nomination details, which will be outlined in a preliminary proxy statement to be filed with the Securities and Exchange Commission (SEC). This document will provide crucial insights into the candidates, their qualifications, and the strategic vision they plan to implement if elected.

Conclusion

Overall, DOMA's strategic action to nominate independent directors represents a significant movement within the governance landscape of Pacira BioSciences. By backing candidates who can provide fresh perspectives and aim to unlock value, DOMA is positioning itself as a key player both as an activist investor and as an advocate for shareholder interests. As stakeholders await further developments, this initiative serves as a reminder of the evolving dynamics of corporate governance and the crucial role investors play in shaping the future of public companies.